pdufa.bio
Home › CRL letters › October 2025

FDA complete response letters, October 2025

Page updated ·next FDA decision on the calendar ·Data as of Nov 10, 2026 12:55 AM ET

The FDA's public release of complete response letters holds 8 letters dated October 2025 (openFDA, last updated 2026-08-26). Of the 22 FDA decisions on PDUFA goal dates pdufa.bio tracked in October 2025, 4 were Complete Response Letters.

Released by the FDA, dated October 2025 · 8

Letter dateCompanyApplicationopenFDA statusLetter
2025-10-31Alvotech USA Inc.BLA 761462Unapprovedletter (PDF)
2025-10-23Shanghai Auzone Biological Technology Co., Ltd.NDA 219846Unapprovedletter (PDF)
2025-10-23GlaxoSmithKline LLCBLA 761440/Original 2, BLA 7Unapprovedletter (PDF)
2025-10-22SYDNEXIS Inc.NDA 219694Unapprovedletter (PDF)
2025-10-21NeuroDerm, Ltd.NDA 218317Unapprovedletter (PDF)
2025-10-16Dr. Reddy’s Laboratories SABLA 761376Unapprovedletter (PDF)
2025-10-10AstraZeneca Pharmaceuticals LPBLA 761451Unapprovedletter (PDF)
2025-10-07Xspray Pharma ABNDA 216195Unapprovedletter (PDF)

Complete Response Letters among decisions pdufa.bio tracked · 4

FDA actionTickerDrugSource
2025-10-17SNSEsource-verifieddecision page
2025-10-17REGNSolnerstotugdecision page
2025-10-13CGEMprice-onlydecision page
2025-10-01FBIOZYCUBOdecision page
A Complete Response Letter is the FDA's notice that it will not approve an application in its current form; it is not a permanent rejection, and the sponsor can resubmit. The two counts come from different records and are not added together. ← September 2025 · November 2025 → · all released letters · every CRL decision we tracked